Skip to Content

Vaccines, Volume 1, Issue 4

2013 December - 8 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (8)

  • Review
  • Open Access
46 Citations
14,490 Views
23 Pages

21 November 2013

The success of cellular immunotherapies against cancer requires the generation of activated CD4+ and CD8+ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a...

  • Article
  • Open Access
16 Citations
9,244 Views
14 Pages

30 October 2013

When HIV was discovered and established as the cause of AIDS in 1983–1984, many people believed that a vaccine would be rapidly developed. However, 30 years have passed and we are still struggling to develop an elusive vaccine. In trying to achieve t...

(This article belongs to the Special Issue HIV Vaccines)
  • Review
  • Open Access
5 Citations
6,206 Views
16 Pages

28 October 2013

Increasing numbers of HIV-infected individuals have access to potent antiretroviral drugs that control viral replication and decrease the risk of transmission. However, there is no cure for HIV and new strategies have to be developed to reach an erad...

(This article belongs to the Special Issue HIV Vaccines)
  • Review
  • Open Access
18 Citations
16,898 Views
16 Pages

28 October 2013

The HIV-1 envelope glycoprotein spike is the target of neutralizing antibody attack, and hence represents the only relevant viral antigen for antibody-based vaccine design. Various approaches have been attempted to recapitulate Env in membrane-anchor...

(This article belongs to the Special Issue HIV Vaccines)
  • Article
  • Open Access
4 Citations
10,204 Views
18 Pages

Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs

  • Stefano Petrini,
  • Giorgio Ramadori,
  • Riccardo Villa,
  • Paolo Borghetti,
  • Elena De Angelis,
  • Anna Maria Cantoni,
  • Attilio Corradi,
  • Augusto Amici and
  • Maura Ferrari

18 October 2013

In veterinary medicine, there have been different experiences with the plasmid DNA vaccination. In this area and with the hypothesis to demonstrate the effectiveness of different plasmids encoding porcine respiratory and reproductive syndrome (PRRS),...

(This article belongs to the Special Issue DNA Vaccines)
  • Review
  • Open Access
28 Citations
13,164 Views
19 Pages

Chemokines as Cancer Vaccine Adjuvants

  • Iuliana D. Bobanga,
  • Agne Petrosiute and
  • Alex Y. Huang

16 October 2013

We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic app...

  • Case Report
  • Open Access
27 Citations
15,404 Views
17 Pages

Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial

  • Larry R. Smith,
  • Mary K. Wloch,
  • Jennifer A. Chaplin,
  • Michele Gerber and
  • Alain P. Rolland

25 September 2013

2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This vaccine consists of two plasmids expressing CMV antigens glycoprotein B (gB) and phosphoprotei...

(This article belongs to the Special Issue DNA Vaccines)
  • Article
  • Open Access
12 Citations
10,108 Views
29 Pages

DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant

  • Sanna Nyström,
  • Andreas Bråve,
  • Tina Falkeborn,
  • Claudia Devito,
  • Björn Rissiek,
  • Daniel X. Johansson,
  • Ulf Schröder,
  • Satoshi Uematsu,
  • Shizuo Akira and
  • Steven E. Applequist
  • + 1 author

25 September 2013

Eliciting effective immune responses using non-living/replicating DNA vaccines is a significant challenge. We have previously shown that ballistic dermal plasmid DNA-encoded flagellin (FliC) promotes humoral as well as cellular immunity to co-deliver...

(This article belongs to the Special Issue DNA Vaccines)
XFacebookLinkedIn
Vaccines - ISSN 2076-393X